RxDoctor Payments Data

Mycal Mansfield, MD

Family Medicine · Avilla, INNPI 1174730071

Payments from drug & device makers

$8,207in general payments, 2019–2025

Across 530 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$818
  • AstraZeneca$785
  • Lilly USA, LLC$549
  • Pfizer$502
  • GSK$490
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,207 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$90,864
Medicare patients
190
Services billed
2,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$135,245
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$83,175
OzempicSemaglutide55$81,399
EliquisApixaban55$64,068
JanuviaSitagliptin Phosphate25$39,828
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$35,896
Tresiba Flextouch U-200Insulin Degludec12$24,396
Tresiba Flextouch U-100Insulin Degludec15$19,282
Breo ElliptaFluticasone/Vilanterol22$17,684
XareltoRivaroxaban11$16,972
TrulicityDulaglutide12$12,034
MounjaroTirzepatide13$11,977
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$11,628
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$11,009
JanumetSitagliptin Phos/Metformin Hcl12$10,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$483$135,245132 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$490$119,471134 claims
Novo NordiskOzempic$818$81,39955 claims
PfizerEliquis, Dilantin$502$66,89567 claims
MerckJanuvia, Janumet$109$50,72037 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$549$25,67043 claims
Johnson & JohnsonXarelto$141$16,97211 claims
AbbVieSynthroid$1,242$2,98338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Avilla

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →